The Transgenic Core works with Investigators to generate animal models what will increase our understanding of cancer and the function of genes in involved in cancer. This Core was established in 1989 and produces transgenic mice and rats, and gene-targeted mice (knockouts) for Cancer Center members. The Transgenic Core maintains specialized equipment for micromanipulation, mouse embryonic stem (ES) cell culture, embryo cryopreservation, bacterial artificial chromosome (BAC) recombineering. This collaborative Core combines the expertise of Center members in the molecular biology of Important genes with the Core's expertise in producing genetically engineered mice, Unique capabilities that set this Transgenic Core apart are 1) guaranteed production of transgenic mice and rats. 2) routine production of BAC transgenic mice, 3) production of transgenic mice In unique genetic backgrounds, 4) gene targeting In C57BL/6 ES cell lines in addition to 129/Sv ES cells, 5) de novo derivation of mouse ES cell lines, 6) genetic modification of BACs, 7) open access to reagents and equipment, and 8) training in ES cell culture and micromanipulation. Access to the Transgenic Core eliminates the need for Investigators to purchase specialized equipment and train personnel in embryo micromanipulation, ES cell culture, and BAG recomblneering. Consultation on all aspects of transgenic and ES cell research is provided, from the design of transgenes and conditional targeting vectors to mouse breeding and phenotype analysis. We deliver an average of nine transgenic founder mice and guarantee that at least three founders will be produced for each DNA construct submitted to the Core, The Core electroporates totipotent ES cells with targeting vectors, selects 480 ES cell clones, and provides Investigators with ES cell DNA to screen for homologous recombination with targeting vectors. We guarantee that ES cell clones with desired genetic changes will be microinjected Into at least 60 mouse blastocysts to produce ES cell-mouse chimeras. The efficiency of these procedures meets or exceeds published values in the literature. A full suite of assisted reproductive technologies is offered;mouse cryopreservation, mouse In vitro fertilization, sperm cryopreservation, recovery of mice from cryopreserved embryos or sperm. Center members have taken advantage of these capabilities to establish develop models of gastric cancer, pancreatic cancer, skin cancer, colon cancer, prostate cancer, breast cancer, and medulioblastoma.

Public Health Relevance

Mouse and rat models of human cancer can be produced by genetic engineering. Scientists can use animal models to see what causes cancer and come up with ideas for treatments that will help sick people feel better. When new medicines are invented they can be tested in rats and mice to see if they work before people try them.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-26
Application #
8696623
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
26
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90
Rosselli-Murai, Luciana K; Yates, Joel A; Yoshida, Sei et al. (2018) Loss of PTEN promotes formation of signaling-capable clathrin-coated pits. J Cell Sci 131:
Cilliers, Cornelius; Menezes, Bruna; Nessler, Ian et al. (2018) Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Res 78:758-768
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Zhou, Bing; Hu, Jiantao; Xu, Fuming et al. (2018) Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem 61:462-481
Lorenz, Daniel A; Vander Roest, Steve; Larsen, Martha J et al. (2018) Development and Implementation of an HTS-Compatible Assay for the Discovery of Selective Small-Molecule Ligands for Pre-microRNAs. SLAS Discov 23:47-54
Chockley, Peter J; Chen, Jun; Chen, Guoan et al. (2018) Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest 128:1384-1396

Showing the most recent 10 out of 1493 publications